You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
李氏大藥廠(00950.HK):Dilafor已入組首名患者進行使用Tafoxiparin治療患有子癲前症孕婦的臨牀2a期研究
格隆匯 10-27 22:38

格隆匯10月27日丨李氏大藥廠(00950.HK)公佈,有關公司與Dilafor AB("Dilafor")(一間瑞典藥物開發公司,專注開發適應於產科的Tafoxiparin)yu 2014年2月訂立d 特許協議,以在中國大陸、香港、澳門及台灣生產、開發及銷售適應於產科及婦科的Tafoxiparin。

於2021年10月22日,Dilafor已入組首名患者進行使用Tafoxiparin治療患有子癲前症孕婦的臨牀2a期研究。此探索性、開放性、隨機、平行組別、2a期先導研究將評估由診斷時間起最多4周的每日皮下Tafoxiparin治療的安全性、耐受性及療效。研究計劃入組23名懷孕介乎26至34周被診斷出患有子癲前症的孕婦。該等孕婦將隨機接受Tafoxiparin皮下注射及標準照護或只接受標準照護(一般為以抗高血壓藥物進行鍼對症候的治療)。

全球各地有5–8%孕婦被診斷出患有子癲前症,此症可導致嚴重母嬰併發症。三分之一屬嚴重個案,有極高風險出現早產及母嬰後遺症。報吿顯示曾患子癲前症的婦女較早出現長期血管併發症(包括中風及心血管問題)。此情況在高收入及低收入國家均為三大孕產婦死亡原因之一。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account